# Rob Woodman

> Rob Woodman is a Series A investor at Panakes Partners backing Health Care and Biotechnology. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Panakes Partners](https://shizune.co/investors/profile/panakes-partners)
- Location: London, United Kingdom
- Total investments: 15
- Last investment: Jan 2024
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/rob-woodman/10/832/8a3

Rob Woodman is a Series A investor at Panakes Partners in London focused on Health Care and Biotechnology. Rob Woodman is Director of Healthcare Investments at Imperial Innovations, and currently serves on the board of Mission Therapeutics, Stanmore Implants, and Nascient Therapeutics. Rob joined Innovations in 2012 and was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Whilst atSofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRUK) through to pharmaceutical consultancy with IMS Health. Rob holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 47% |
| Biotechnology | 7 | 47% |
| Therapeutics | 4 | 27% |
| Medical | 2 | 13% |
| Medical Device | 2 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 33% |
| Series B | 3 | 20% |
| Funding Round | 2 | 13% |
| Series C | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 5 | 33% |
| United States | 2 | 13% |
| Israel | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enterprise Therapeutics | Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. | $33.1M | Series B | Jan 29, 2024 |  |
| Complement Therapeutics | Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M | Series A | Apr 17, 2023 |  |
| Catamaran Bio | Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. It offers cell therapy company developing allogeneic, off-the-shelf products for patients with an unmet medical need. It was founded in 2020 and headquartered in Cambridge, Massachusetts. | $42M | Series A | Nov 23, 2020 |  |
| BIOMx | BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $32M | Series B | Feb 20, 2019 |  |
| MISSION Therapeutics | Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $78.6M | Series C | Feb 02, 2016 |  |
| Inivata | Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collectedthrough a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated. | $41.2M | Series A | Jan 26, 2016 |  |
| Inivata | Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collectedthrough a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated. | $5.2M |  | Sep 23, 2014 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $2.6M | Series A | Apr 03, 2014 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $2.6M | Series A | Apr 03, 2014 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $22.9M | Series A | Dec 17, 2013 |  |

10 of 15 investments shown.

## Co-investors
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 5 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 4 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 4 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 4 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 3 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 3 deals together

## About Panakes Partners

VC Fund · Milano, Italy

Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250million under management.

5 contacts available at Panakes Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alessio Beverina | Co-Founder & General Partner | https://shizune.co/investors/profile/alessio-beverina |
| Fabrizio Landi | Founder and Managing Partner | https://shizune.co/investors/profile/fabrizio-landi |
| Barbara Castellano | Partner | https://shizune.co/investors/profile/laura-iris-ferro |
| Diana Saraceni | General partner | https://shizune.co/investors/profile/diana-saraceni |
| Rob Woodman | Partner | https://shizune.co/investors/profile/rob-woodman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Rob Woodman invest in?

Rob Woodman invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Rob Woodman last invest?

The most recent investment recorded for Rob Woodman closed in Jan 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co